This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a ...

Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

NEW YORK & GENEVA--(BUSINESS WIRE)--Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched today ...

Researchers at the Centre for Genomic Regulation and the Wellcome Sanger Institute have comprehensively identified the allosteric control sites found in the protein KRAS, which is one of the most ...

Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC). The 15-gene expression profile test is independent from PRAME and ...

Sir2, an enzyme belonging to sirtuins, has been effectively involved in the deacetylation of proteins. A tandem allosteric effect of reactant and product is responsible for the efficient deacetylation ...

Neurodegenerative diseases such as Parkinson’s remain some of the most difficult conditions to treat, with current therapies focused largely on managing symptoms rather than altering the course of the ...

An illustration of the results of the trans-omic analysis. Allosteric regulation, which controls metabolism, decreased in typical mice during feeding (thin blue arrow, left) and increased during ...